Solventum Corporation SOLV
Nov 5, 2026, 10:33 AM EST
- YTD
- +12.29%
- 1 year
- +31.44%
- Market cap
- 15.14B
- Revenue (ttm)
- 8.31B
- Profit margin
- 17.26%
- EPS (ttm)
- 8.17
- Shares out
- 170.22M
- P/E ratio
- 10.88
- Forward P/E
- 12.29
- YTD return
- +12.29%
- 1-year return
- +31.44%
- Volume
- 158.86K
- Avg volume
- 1.04M
- Open
- 90.34
- Previous close
- 89.35
- Day's range
- 88.00 – 90.26
- 52-week range
- 62.49 – 92.44
- Beta
- 0.75
- Analysts
- Buy
- Price target
- 94.69 (+6.4%)
- Earnings date
- Nov 5, 2026
5D +5.43 (+6.49%)
Key statistics
- Enterprise value
- 19.32B
- PEG ratio
- 1.22
- Price / sales
- 1.83
- Price / book
- 3.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.20%
- Free cash flow
- 489.00M
- Total cash
- 403.00M
- Total debt
- 5.30B
- Return on equity
- 33.96%
- Short % of float
- 3.43%
- 50-day average
- 87.87
- 200-day average
- 78.42
Analyst view
Consensus: buy
- Target (low)
- 71.00
- Target (mean)
- 94.69
- Target (high)
- 113.00
- Strong buy1
- Buy7
- Hold5
- Sell1
- Strong sell1
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 1.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 1.34 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 1.90 | 2.55 | +0.65 | +34.21% |
| May 5, 2026 | Mar 31, 2026 | 1.35 | 1.48 | +0.13 | +9.63% |
| Feb 26, 2026 | Dec 31, 2025 | 1.50 | 1.57 | +0.07 | +4.67% |
| Nov 6, 2025 | Sep 30, 2025 | 1.43 | 1.50 | +0.07 | +4.90% |
| Aug 7, 2025 | Jun 30, 2025 | 1.45 | 1.69 | +0.24 | +16.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 2026 | BTIG | reit | Buy | Buy |
| Aug 6, 2026 | UBS | main | Buy | Buy |
| Aug 6, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 6, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 6, 2026 | Keybanc | main | Overweight | Overweight |
| Aug 6, 2026 | Stifel | main | Buy | Buy |
About Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- solventum.com
News
Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key Metrics
SOLV Energy Expands High-Voltage Infrastructure Capabilities with Acquisition of ASB Energy Services
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Here's Why Solventum (SOLV) is a Strong Value Stock Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy
UBS Maintains Buy on Solventum, Raises Price Target to $101
Piper Sandler Maintains Overweight on Solventum, Raises Price Target to $105
Wedbush Maintains Outperform on Solventum, Raises Price Target to $101
Keybanc Maintains Overweight on Solventum, Raises Price Target to $102
Your note
Sign in to keep a note on SOLV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 3M CO | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 14, 2025 | 25,569,200 |
| COX CARRIE SMITH | Director | Conversion of Exercise of derivative security | Apr 29, 2026 | 16,400 |
| GOMEZ TAMMY L | Officer | Conversion of Exercise of derivative security | May 12, 2026 | 13,362 |
| HANSON BRYAN CRAIG | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 31, 2026 | 185,515 |
| HARRINGTON PAUL S | Officer | Conversion of Exercise of derivative security | May 12, 2026 | 20,452 |
| KIRBERGER MARCELA A. | Officer | Conversion of Exercise of derivative security | May 12, 2026 | 13,540 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Independent Franchise Partners, LLP | 9.50% | 16,170,038 | 1.44B | Jun 29, 2026 |
| Blackrock Inc. | 5.73% | 9,761,863 | 871.83M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.65% | 9,624,829 | 859.59M | Jun 29, 2026 |
| Trian Fund Management, LP | 4.84% | 8,236,753 | 735.62M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.72% | 6,328,641 | 565.21M | Jun 29, 2026 |
| Davis Selected Advisers | 3.71% | 6,307,729 | 563.34M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.75% | 4,674,934 | 417.52M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.24% | 3,816,022 | 340.81M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.98% | 3,375,087 | 301.43M | Jun 29, 2026 |
| John Hancock Funds III-Disciplined Value Mid Cap Fund | 1.40% | 2,385,590 | 213.06M | Aug 30, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.28% | 2,172,808 | 194.05M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.26% | 2,138,463 | 190.99M | Jun 29, 2026 |
